Capecitabine Tablets

Capecitabine is an oral chemotherapy drug with selective targeting effect on tumor cells. Capecitabine itself is non-cytotoxic and can be activated into cytotoxic 5-fluorouracil in tumor cells through a three-step enzyme chain reaction, thereby minimizing the damage of 5-fluorouracil to normal human cells.

Capecitabine

This product is a colorless transparent liquid.

FDA approved for the treatment of metastatic breast cancer that is resistant to conventional therapies and for the treatment of metastatic colorectal cancer in combination with Taxotere for the treatment of advanced breast cancer.

The recommended dose is 2,500 mg/m2 per day, for two weeks, followed by a one-week break. The total daily dose should be taken twice a day, morning and evening, with water half an hour after meals.

Xeloda has fewer adverse reactions, and the following conditions may be related to it: Digestive system: The most common adverse reactions of Xeloda are reversible gastrointestinal reactions, such as diarrhea, nausea, vomiting, abdominal pain, gastritis, etc. Severe (grade 3-4) adverse reactions are relatively rare. Skin: Hand-foot syndrome occurs in almost half of the patients using Xeloda: manifested as numbness, insensitivity, paresthesia, tingling, painlessness or pain, skin swelling or erythema, desquamation, blisters or severe pain. Dermatitis and alopecia are common, but severe cases are rare. General adverse reactions: Fatigue is common, but severe cases are extremely rare. Other common adverse reactions are mucositis, fever, weakness, drowsiness, etc., but none of them are serious.

Patients with a history of severe side effects to Xeloda or hypersensitivity to fluoropyrimidines (metabolites of capecitabine) are contraindicated in using Xeloda.

Precautions for children: The safety and efficacy of capecitabine for patients under 18 years of age have not been confirmed. Precautions for pregnancy and lactation: Clinical studies of this product have not been conducted in pregnant women, but it must be considered that if this product is used in such patients, it may cause fetal damage. Animal experiments have shown that capecitabine can cause fetal death or malformation. These findings indicate that capecitabine derivatives also have this effect, so this product should not be used in pregnant women. If this product is used during pregnancy or pregnancy occurs during the use of this product, the potential risk of fetal damage or malformation must be considered. Women of childbearing age must take contraceptive measures when using this product. Although it is not known whether this product can be secreted in breast milk, since many drugs can be secreted in breast milk and have the potential risk of causing serious side effects to breastfeeding infants, it is recommended that women using this product stop breastfeeding. Precautions for the elderly: No dose adjustment is required. However, the elderly (over 65 years old) are more susceptible to toxicity to capecitabine than young people, so they should be closely monitored.

Xeloda has been used in combination with a large number of drugs, such as antihistamines, NSAIDs, morphine, paracetamol, aspirin, antiemetics, H2 receptor antagonists, etc., without clinically significant side effects. Protein binding: Capecitabine has a low binding rate to serum proteins (64%). The possibility of interaction with drugs that are tightly bound to proteins through displacement cannot be predicted. Interaction with cytochrome P450 enzymes: In in vitro experiments, capecitabine was not found to affect human liver microsomal P450 enzymes.

Sealed storage

0.15 g

24 months